Free tool
Oncology stocks
We cover 165 companies grouped under the Oncology theme. The median market value in the group is $751.23M. Across the group, the median move over the past trading day is +1.50%. 65% of the 159 with a 200-day average trade above it. Price change over the past year runs from −27.7% to +312.4% across the middle 80 percent of the group, with a median of +35.4%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
165 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | $380.73B | Mega cap | +83.96% |
| MRK | Merck & Co., Inc. | $371.70B | Mega cap | +88.17% |
| AZN.L | AstraZeneca PLC | $264.05B | Mega cap | +1.98% |
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +7.60% |
| A1ZN34.SA | AstraZeneca PLC | $260.90B | Mega cap | +1.51% |
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $73.00B | Large cap | +12.47% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% |
| 4568.T | Daiichi Sankyo Company, Limited | $33.36B | Large cap | −15.95% |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% |
| GE9.DE | GENMAB AS N | $21.11B | Large cap | −14.41% |
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.55% |
| IPN.PA | Ipsen S.A. | $16.01B | Large cap | +39.21% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| 0IJO.L | Exelixis, Inc. | $14.05B | Large cap | +44.33% |
| 0M2N.L | Orion Oyj | $11.16B | Large cap | +19.68% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +62.22% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| 000100.KS | Yuhan Corporation | $4.67B | Mid cap | −25.59% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $4.54B | Mid cap | +75.99% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.91B | Mid cap | −12.72% |
| 000105.KS | Yuhan Corporation | $3.88B | Mid cap | −31.05% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| HCM.L | HUTCHMED (China) Limited | $2.12B | Mid cap | −21.24% |
| NANO.PA | Nanobiotix S.A. | $2.12B | Mid cap | +341.09% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| ZYME | Zymeworks Inc. | $1.96B | Small cap | +88.54% |
| IMCR | Immunocore Holdings plc | $1.93B | Small cap | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $1.89B | Small cap | +800.59% |
| GXE.DE | Lakefront Biotherapeutics NV | $1.89B | Small cap | −44.50% |
| VIR | Vir Biotechnology, Inc. | $1.81B | Small cap | +144.52% |
| INBX | Inhibrx Biosciences, Inc. | $1.81B | Small cap | +390.10% |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.77B | Small cap | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $1.63B | Small cap | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $1.57B | Small cap | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $1.55B | Small cap | +62.02% |
| REPL | Replimune Group, Inc. | $1.49B | Small cap | +187.80% |
| AKTS | Aktis Oncology, Inc. | $1.48B | Small cap | +19.15% |
| CGEM | Cullinan Therapeutics, Inc. | $1.48B | Small cap | +200.39% |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.40B | Small cap | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $1.36B | Small cap | +357.94% |
| IMTX | Immatics N.V. | $1.26B | Small cap | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.24B | Small cap | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.22B | Small cap | +167.16% |
| 0HFQ.L | AnaptysBio, Inc. | $1.20B | Small cap | +183.92% |
| 2160.T | GNI Group Ltd. | $1.14B | Small cap | +4.54% |
| JANX | Janux Therapeutics, Inc. | $1.14B | Small cap | −18.82% |
| PHIL.MI | Philogen S.p.A. | $1.12B | Small cap | +2.12% |
| KURA | Kura Oncology, Inc. | $1.10B | Small cap | +77.65% |
| CADL | Candel Therapeutics, Inc. | $1.04B | Small cap | +138.18% |
| GERN | Geron Corporation | $995.83M | Small cap | +9.15% |
| EUZ.DE | Eckert & Ziegler SE | $963.05M | Small cap | −23.06% |
| OLMA | Olema Pharmaceuticals, Inc. | $954.60M | Small cap | +95.17% |
| 4587.T | PeptiDream Inc. | $902.75M | Small cap | −28.26% |
| ANL | Adlai Nortye Ltd. | $884.83M | Small cap | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $864.97M | Small cap | +14.75% |
| AURA | Aura Biosciences, Inc. | $810.97M | Small cap | +19.94% |
| NVCT | Nuvectis Pharma, Inc. | $777.72M | Small cap | +298.92% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $751.23M | Small cap | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $747.47M | Small cap | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $734.32M | Small cap | +68.50% |
| 4588.T | Oncolys BioPharma Inc. | $716.01M | Small cap | +526.71% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $707.84M | Small cap | +5.13% |
| GUD.TO | Knight Therapeutics Inc. | $692.32M | Small cap | +49.08% |
| EIKN | Eikon Therapeutics, Inc. | $679.77M | Small cap | −16.33% |
| 0QAV.L | Nanobiotix S.A. | $671.98M | Small cap | +346.30% |
| CU6.AX | Clarity Pharmaceuticals Ltd | $669.65M | Small cap | −27.91% |
| VSTM | Verastem, Inc. | $641.19M | Small cap | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $639.61M | Small cap | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $630.33M | Small cap | +15.65% |
| ARVN | Arvinas, Inc. | $610.71M | Small cap | +28.34% |
| DCTH | Delcath Systems, Inc. | $587.10M | Small cap | +55.37% |
| 0KCS.L | OPKO Health, Inc. | $578.38M | Small cap | +5.63% |
| PRLD | Prelude Therapeutics Incorporated | $524.86M | Small cap | +418.90% |
| CCCC | C4 Therapeutics, Inc. | $516.71M | Small cap | +66.01% |
| TOI | Starling Oncology Inc | $512.91M | Small cap | +78.67% |
| 0IL8.L | Kyntra Bio, Inc. | $512.46M | Small cap | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | $494.50M | Small cap | −91.09% |
| RLMD | Relmada Therapeutics, Inc. | $489.61M | Small cap | +635.58% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | $472.39M | Small cap | +1150.00% |
| PBYI | Puma Biotechnology, Inc. | $470.77M | Small cap | +86.77% |
| 0LOV.L | Verastem, Inc. | $470.33M | Small cap | −21.47% |
| CMPX | Compass Therapeutics, Inc. | $455.62M | Small cap | −16.23% |
| AVCT.L | Avacta Group Plc | $444.39M | Small cap | +32.31% |
| FENC | Fennec Pharmaceuticals Inc. | $410.64M | Small cap | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $406.79M | Small cap | +30.48% |
| PRTC.L | PureTech Health plc | $402.61M | Small cap | −11.34% |
| GALT | Galectin Therapeutics Inc. | $402.39M | Small cap | −0.25% |
| FRX.TO | Fennec Pharmaceuticals Inc. | $392.65M | Small cap | +27.38% |
| AGEN | Agenus Inc. | $376.28M | Small cap | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $375.56M | Small cap | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $367.33M | Small cap | +113.19% |
| STRO | Sutro Biopharma, Inc. | $355.50M | Small cap | +155.24% |
| 0XOD.L | UroGen Pharma Ltd. | $347.24M | Small cap | +136.32% |
| IMRX | Immuneering Corporation | $338.37M | Small cap | −12.10% |
| BCYC | Bicycle Therapeutics plc | $306.47M | Small cap | −38.34% |
| RAC.AX | Racura Oncology Ltd | $303.46M | Small cap | +72.00% |
| WHWK | Whitehawk Therapeutics, Inc. | $278.20M | Small cap | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $276.55M | Small cap | +81.82% |
| CGEN | Compugen Ltd. | $271.86M | Small cap | +100.70% |
| MGNX | MacroGenics, Inc. Common Stock | $265.63M | Small cap | +154.27% |
| TNG.PA | Transgene SA | $261.88M | Small cap | −16.98% |
| GLSI | Greenwich LifeSciences, Inc. | $258.04M | Small cap | +56.35% |
| 0IV3.L | Geron Corporation | $255.34M | Small cap | +8.41% |
| PYXS | Pyxis Oncology, Inc. | $255.23M | Small cap | +120.14% |
| IPHA | Innate Pharma S.A. | $253.56M | Small cap | +1.34% |
| SPL.AX | Starpharma Holdings Limited | $252.95M | Small cap | +465.38% |
| ADAG | Adagene Inc. | $252.40M | Small cap | +62.55% |
| IDD.DE | Innate Pharma S.A. | $247.30M | Small cap | −2.52% |
| IPH.PA | Innate Pharma S.A. | $244.95M | Small cap | +1.84% |
| TARA | Protara Therapeutics, Inc. | $234.61M | Small cap | +30.16% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $218.75M | Small cap | +14.36% |
| NBP | NovaBridge Biosciences | $218.58M | Small cap | −59.96% |
| CHRS | Coherus Oncology, Inc. | $211.67M | Small cap | +17.09% |
| BINV.ST | BioInvent International AB (publ) | $169.15M | Small cap | −24.30% |
| MENS | Jyong Biotech Ltd. | $168.78M | Small cap | −95.26% |
| CUE | Cue Biopharma, Inc. | $168.39M | Small cap | +9.05% |
| MOLN | Molecular Partners AG | $164.30M | Small cap | +3.91% |
| KZIA | Kazia Therapeutics Limited | $157.58M | Small cap | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $155.52M | Small cap | +36.77% |
| ASRT | Assertio Holdings Inc | $151.86M | Small cap | +98.31% |
| INDP | Indaptus Therapeutics, Inc. | $145.90M | Small cap | −84.51% |
| 0IMT.L | Photocure ASA | $144.18M | Small cap | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | $137.67M | Small cap | −44.40% |
| SCLP.L | Scancell Holdings plc | $137.37M | Small cap | −6.67% |
| ADCT | ADC Therapeutics SA | $132.77M | Small cap | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $130.00M | Small cap | −30.85% |
| 0RU5.L | Oncoinvent ASA | $128.23M | Small cap | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $127.21M | Small cap | +76.16% |
| LIXT | Nomad Power Solutions Inc | $125.36M | Small cap | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $123.81M | Small cap | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $123.16M | Small cap | +22.00% |
| GNLX | Genelux Corporation | $123.07M | Small cap | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $122.16M | Small cap | −18.72% |
| 0RDB.L | Oryzon Genomics S.A. | $121.50M | Small cap | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | $117.79M | Small cap | −34.72% |
| 4889.T | Renascience Inc. | $117.04M | Small cap | −37.68% |
| FARN.L | Faron Pharmaceuticals Oy | $113.51M | Small cap | −80.71% |
| HBP.TO | Helix BioPharma Corp. | $109.87M | Small cap | +35.37% |
| ONCY | Oncolytics Biotech Inc. | $109.84M | Small cap | −12.99% |
| AMAN | Amanat Acquisition Corp | $103.43M | Small cap | +6.79% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.